The Senator Who Wouldn't Take Half a Win: Cory Booker, Cannabis, and the Cost of Purity

Cory Booker has introduced more cannabis reform legislation than any sitting senator in American history. He has called the War on Drugs "a war on people." He went on a 10-day hunger strike in Newark to draw attention to open-air drug markets. He authored the bill that became the template for every serious federal legalization proposal since 2017. NORML gave him an A+.

And yet, across the cannabis industry — from multistate operators to single-license social equity applicants — the mention of Cory Booker's name is as likely to draw a groan as a thank-you.

Because Cory Booker also spent two critical years blocking the one cannabis reform bill that could actually pass: the SAFE Banking Act. He did it on principle. And while he held the line, people got robbed. Businesses failed. The window closed.

This is the story of a senator who may have done more to advance — and more to stall — cannabis reform than anyone else in Washington. It's a story about what happens when the pursuit of a perfect bill becomes the enemy of the good one. About pharmaceutical money, strategic miscalculations, and the gap between moral clarity and legislative results.

Chapter 1: The Streets of Newark

Before Cory Booker was a senator with a microphone, he was a Yale Law School graduate who moved into Brick Towers, one of the most dangerous public housing projects in Newark, New Jersey. He arrived in 1997 and didn't leave for eight years.

As a city council member starting in 1998, Booker staged what the political establishment dismissed as stunts but what residents saw as solidarity. He camped out on street corners to spotlight open-air drug markets. He went on a 10-day hunger strike, living in a tent near drug-dealing areas. He was regularly outvoted 8-to-1 by the Newark Democratic machine.

When he became mayor in 2006, he inherited a city drowning in the consequences of the War on Drugs — a police department whose director had been jailed for stealing money meant to fund anti-drug operations, courts that set low bail for armed offenders, and communities where marijuana arrests were a conveyor belt into the criminal justice system.

Booker created Newark's first office of prisoner re-entry. He implemented reentry programs, court reform initiatives, and jobs programs targeted at formerly incarcerated residents. His police department, led by a former NYPD deputy commissioner, drove violent crime down significantly — Newark led the nation in crime reduction from 2006 to 2008.

But a tension existed even then. Civil rights groups criticized Booker for giving too much leeway to aggressive policing tactics in his push to reduce violence. A New York Times deep dive into his criminal justice record noted this friction. Booker's own police were, as he admitted on Reddit in 2012, "involved in an almost ridiculous game of arresting the same people over and over again."

He saw the machine from the inside. He knew what it produced. And he came to the Senate in 2013 with what appeared to be genuine conviction that the drug war's wreckage demanded a comprehensive response — not piecemeal fixes.

Chapter 2: Big Pharma's Favorite Progressive

Before Booker became cannabis reform's loudest voice, he had a different reputation: as the Democratic senator most financially entangled with the pharmaceutical industry.

New Jersey is America's pharmaceutical corridor. Johnson & Johnson, Merck, Novartis, Bristol-Myers Squibb — the state's economy is woven through with drug manufacturing. And when Booker ran for Senate in 2013 and 2014 (a special election followed by a regular cycle), the industry showed its appreciation. He raised roughly $330,000 from pharmaceutical company PACs and employees across those campaigns — more than any other Democratic senator during that period, and second overall only to Mitch McConnell.

For the progressive base, this created a credibility problem that Booker has never fully escaped.

The breaking point came in January 2017. Senator Bernie Sanders introduced a symbolic amendment encouraging the federal government to allow Americans to purchase cheaper prescription drugs from Canada. It had overwhelming public support — 72% of Americans backed importation. Donald Trump had even campaigned on it.

The amendment failed 52-46. Thirteen Republicans crossed party lines to vote yes. Thirteen Democrats crossed to vote no. Booker was one of them.

The backlash was immediate and fierce. Progressives noted that Booker had received more pharmaceutical manufacturing money over the previous six years than any Democratic senator who opposed the amendment — $267,338 according to MapLight. Hours before the vote, Booker had positioned himself as a progressive champion by becoming the first senator to testify against a sitting colleague at Jeff Sessions's confirmation hearing. Now he was voting with the pharmaceutical industry against cheaper drugs.

Booker's defense was that the amendment lacked safety standards for imported drugs — an argument the industry itself had used for years. Former Minnesota Governor Tim Pawlenty, a Republican, had once responded to that claim by asking: "Show me the dead Canadians." Most drugs that would be imported from Canada were originally manufactured in the United States.

The episode left a mark. Booker eventually put a "pause" on pharmaceutical donations in mid-2017 — a pause that became permanent. By 2018, he swore off all corporate PAC money. He co-sponsored a revised drug importation bill with Sanders that included the safety standards he'd demanded. He appeared at Sanders's press conference on lowering drug prices.

The pharmaceutical money dried up. But the perception lingered — and it would color how the cannabis industry received his later strategic decisions.

Chapter 3: The Marijuana Justice Act — The Template

On August 1, 2017, Booker introduced the Marijuana Justice Act via Facebook Live. It was, at the time, the most comprehensive cannabis reform bill ever introduced in Congress.

The bill would remove marijuana from the Controlled Substances Act entirely — not reschedule it, not move it to Schedule III, but deschedule it completely. It would automatically expunge federal convictions for marijuana use and possession. It would create a community reinvestment fund to invest in communities devastated by the drug war. And critically, it would penalize states where marijuana enforcement was shown to be racially disproportionate by withholding federal funding.

That last provision was the most radical element and the one that distinguished Booker's approach from every other proposal. It wasn't just legalization. It was accountability.

The bill attracted co-sponsors including Sanders, Kamala Harris, Elizabeth Warren, Kirsten Gillibrand, and Ron Wyden. The Drug Policy Alliance called it "the most ambitious marijuana bill we have seen in Congress." It became the conceptual foundation for the MORE Act (which passed the House) and later the Cannabis Administration and Opportunity Act (CAOA), which Booker co-authored with Schumer and Wyden.

Booker's framing was consistent and morally pointed: "The War on Drugs has not been a war on drugs — it's been a war on people, and disproportionately people of color and low-income individuals." He spoke about former presidents and vice presidents who had admitted to drug use without legal consequences, while young people in Newark carried marijuana convictions that permanently scarred their employment, housing, and educational prospects.

On the merits, Booker's argument was unassailable. On the strategy, it was about to become the most controversial decision in modern cannabis politics.

Chapter 4: "I Will Lay Myself Down"

By 2021, the cannabis industry had a real legislative path forward — and it wasn't Booker's comprehensive bill.

The SAFE Banking Act, introduced by Representative Ed Perlmutter of Colorado, would protect banks and credit unions from federal penalties for serving state-legal marijuana businesses. It wouldn't legalize anything. It wouldn't expunge any records. It wouldn't create social equity programs. But it would solve one of the industry's most dangerous practical problems: the fact that cannabis businesses were forced to operate on a cash-only basis because banks feared federal prosecution.

That cash problem wasn't theoretical. Dispensary employees and delivery drivers were being robbed at gunpoint. Some were killed. Businesses couldn't get loans, lines of credit, or even basic checking accounts. Small operators — disproportionately the social equity licensees Booker championed — were the ones most crushed by the lack of banking access, because large multistate operators had the resources to find workarounds.

The SAFE Banking Act passed the House six times. It had bipartisan support in the Senate. It was, by almost universal consensus, the one piece of cannabis legislation that could become law.

In July 2021, at the press conference unveiling the CAOA discussion draft, Booker made his position explicit.

"I will lay myself down to do everything I can to stop an easy banking bill that's going to allow all these corporations to make a lot more money off of this, as opposed to focusing on the restorative justice aspect," he said.

He wasn't being metaphorical. Together with Schumer, Booker ensured that the SAFE Banking Act was stripped from the National Defense Authorization Act (NDAA) after the House had included it. The banking bill, which had the votes to pass, was killed.

The strategy was straightforward: hold banking hostage as leverage to force comprehensive reform. If the industry could get banking without legalization, Booker and Schumer reasoned, it would lose its motivation to push for the harder bill. SAFE Banking was, in Booker's framing, a "sweetener" that should only pass as part of a package that included expungement and social equity.

The industry reacted with something between disbelief and fury.

"The significant majority of cannabis businesses are small businesses, many of which are women or BIPOC operated," responded Beau Whitney of Whitney Economics. "By not having access to traditional financial services such as bridge loans, insurance, or credit card services, these small business owners are disproportionately impacted by the lack of banking services."

The cruelest irony was that the very people Booker said he was protecting — minority-owned small businesses — were the ones being hurt most by the banking blockade. Large MSOs already had banking relationships through various workarounds. It was the social equity applicants, the single-license operators, the small dispensaries in underserved communities who couldn't get a checking account.

Booker clarified his position days later, telling Yahoo Finance: "Don't get me wrong, I support the SAFE Banking Act. I think it's a phenomenal bill." But his clarification didn't change his strategy. The bill stayed blocked.

Chapter 5: The Window That Closed

The CAOA, when finally introduced in July 2022, was 296 pages long. It included federal descheduling, a new regulatory framework under the FDA, a 25% federal excise tax (phased in over five years), social equity grant programs, expungement provisions, and a Cannabis Justice Office at the Department of Justice.

It was everything Booker wanted. It was also dead on arrival.

The bill needed 60 votes to overcome a filibuster. Even a simple legalization bill — with none of the taxes, regulations, or equity provisions — would have been a long shot. By filling CAOA with provisions that Republicans would never support, Booker and Schumer guaranteed that their comprehensive vision would remain exactly that: a vision.

Minutes after the senators' press conference unveiling the CAOA, White House Press Secretary Jen Psaki was asked about the bill. "Nothing has changed" regarding President Biden's opposition to legalization, she said.

The bill went nowhere. It was reintroduced in 2023 and again in 2024. Each time, it attracted attention and praise from advocates. Each time, it failed to receive a floor vote.

Meanwhile, the SAFE Banking Act continued to pass the House, continued to attract bipartisan Senate support, and continued to be blocked from advancing. The window that existed in 2021-2022 — when Democrats controlled both chambers and could have passed banking reform — closed permanently in January 2023 when Republicans took the House.

By September 2023, Booker quietly reversed course. He signed on as a co-sponsor of the SAFER Banking Act, the revised version of the bill he had spent two years blocking. Schumer included assurances that the HOPE Act (providing grants for states to expunge cannabis records) would be incorporated into the bill on the Senate floor.

"With the assurance of Majority Leader Schumer that the HOPE Act...will be incorporated into this legislation on the Senate floor, I'm cosponsoring the SAFER Banking Act," Booker said.

For the industry, the reversal was validating — and infuriating. Booker's about-face confirmed what operators had been arguing for two years: banking reform was both necessary and achievable, and holding it hostage had accomplished nothing except prolonging the suffering of the people Booker claimed to champion.

Chapter 6: The Pharmaceutical Question

The cannabis industry's frustration with Booker can't be separated from the pharmaceutical shadow that follows him.

When Booker blocked SAFE Banking in 2021, cannabis operators didn't just see a senator making a strategic play for comprehensive reform. Many saw the same senator who had voted against Canadian drug imports while pocketing pharmaceutical money — now blocking a bill that would help cannabis compete with the same pharmaceutical industry that had funded his career.

This perception is unfair in some respects. Booker stopped taking pharmaceutical money in 2017. His legislative record on cannabis reform is genuinely more ambitious than any other senator's. The Marijuana Justice Act, the CAOA, his consistent A+ NORML rating, his willingness to hold hearings on decriminalization as Judiciary Subcommittee chairman — these aren't performative.

But perception matters in politics, and the sequence of events created a narrative that Booker has never fully shaken: a senator from Big Pharma's home state, who took their money for years, who voted against cheaper drugs, and who later blocked the one cannabis reform that had bipartisan traction — all while insisting he was doing it for the little guy.

The cannabis industry's relationship with the pharmaceutical sector is inherently adversarial. Every patient who manages pain, anxiety, or insomnia with cannabis is a patient who might otherwise use a pharmaceutical product. When Booker held up banking reform that would have strengthened cannabis businesses, some in the industry saw a senator whose instincts — regardless of his stated principles — consistently aligned with pharmaceutical interests.

This reading may be cynical. But cynicism in cannabis politics is earned.

Chapter 7: The Contradiction — Results vs. Rhetoric

Booker's cannabis record presents a genuine paradox.

On one hand, he has been more right about the moral dimensions of cannabis reform than almost anyone in Congress. His insistence on pairing legalization with expungement and community reinvestment set the terms of every serious cannabis reform debate since 2017. Before Booker's Marijuana Justice Act, most legalization proposals were transactional — remove the prohibition, regulate the market, collect the taxes. Booker forced the conversation to include the people the prohibition had destroyed.

On the other hand, his strategic choices produced exactly the outcome he was trying to prevent. By holding SAFE Banking hostage, he didn't get comprehensive reform — he got nothing. The CAOA never came close to passing. The communities he championed went another two years without banking access. Small operators closed. Employees were robbed. And the large corporations Booker railed against — the ones with the resources to navigate a cash-only industry — were the ones best positioned to survive.

The Reason article that chronicled his reversal put it bluntly: Booker "bemoans the 'cannabis crisis' he helped maintain in Congress by blocking the SAFE Banking Act."

Booker's defenders argue that without the threat of withholding banking, there would have been zero momentum for any broader reform. That SAFE Banking alone would have been a gift to large operators at the expense of equity. That sometimes you have to hold the line even when it hurts.

His critics argue that governing is about outcomes, not intentions. That the perfect bill that never passes helps no one. That two years of blocked banking reform caused real, measurable harm to the exact communities Booker invoked in every speech. And that when he finally co-sponsored SAFER Banking in 2023, he proved his own critics right — the reform was always necessary, and the delay was always unjustified.

Chapter 8: Newark to Now — The Full Arc

To understand Booker's cannabis story, you have to hold two truths simultaneously.

The first truth: Cory Booker changed the conversation about cannabis in America. Before him, legalization was a libertarian issue or a stoner issue or, at best, a states' rights issue. Booker made it a civil rights issue. He connected marijuana policy to mass incarceration, racial disparities in policing, and economic devastation in Black and Brown communities in a way that transformed the political landscape. Every social equity provision in every state legalization bill owes something to the framework he established.

The second truth: Cory Booker's strategic choices between 2021 and 2023 caused direct harm to the cannabis industry and the communities he serves. By blocking achievable reform in pursuit of comprehensive reform that was never achievable, he chose moral consistency over practical results. He was right about what the law should be. He was wrong about what was possible. And the people who paid for that miscalculation were not the multistate operators he criticized — it was the small businesses, the social equity licensees, the dispensary workers who couldn't get a bank account and had to carry cash through neighborhoods where everyone knew they were carrying cash.

The pharmaceutical money is a footnote now — Booker cleaned that up years ago. But the pattern it established echoes through his cannabis record: a senator who talks about the most vulnerable, who introduces the most ambitious legislation, and who — when the moment comes to accept an imperfect solution that would help real people right now — hesitates. Calculates. Holds the line.

As Booker wrote in his book United: "I was coming from college campuses and towns where marijuana, ecstasy, cocaine, and other drugs were widespread and often used openly, with little fear of the police. The war on drugs has turned out to be a war on PEOPLE."

He's right. It always was. And in the years when he had the power to deliver a partial ceasefire, he demanded unconditional surrender.

The surrender never came. The war continued. And the casualties mounted.

Timeline: Booker's Cannabis and Drug Policy Record

1998 — Wins Newark City Council seat; stages 10-day hunger strike near drug-dealing areas to spotlight open-air drug markets.

2006 — Becomes Mayor of Newark; creates city's first office of prisoner re-entry. Implements zero-tolerance policing that draws criticism from civil rights groups.

2012 — Calls the drug war "ineffective" on Reddit, says Newark police are "involved in an almost ridiculous game of arresting the same people over and over again."

2013 — Wins special election to U.S. Senate. Begins receiving substantial pharmaceutical industry donations ($330K+ across 2013-2014 campaigns).

2015 — Co-sponsors bipartisan CARERS Act to protect state medical marijuana programs from federal prosecution.

2017 (January) — Votes against Sanders-Klobuchar amendment on prescription drug imports from Canada. Faces intense progressive backlash over pharmaceutical industry ties. Later puts a "pause" on pharma donations.

2017 (August) — Introduces the Marijuana Justice Act, the first congressional bill pairing federal legalization with expungement and community reinvestment. Earns A+ from NORML.

2018 — Swears off all corporate PAC money. Co-authors the First Step Act (criminal justice reform), signed into law by President Trump.

2019 — Reintroduces Marijuana Justice Act with Rep. Barbara Lee and Rep. Ro Khanna. Runs for president with cannabis reform as a centerpiece issue. Drops out January 2020.

2021 (February) — Announces joint effort with Schumer and Wyden on comprehensive cannabis legislation.

2021 (July) — Unveils CAOA discussion draft. Vows to "lay myself down" to block SAFE Banking Act. Successfully strips SAFE Banking from the NDAA.

2022 (July) — Formally introduces the 296-page CAOA. Holds Senate Judiciary subcommittee hearing on decriminalization. Bill receives no floor vote.

2022 (August) — Signals openness to "SAFE Banking Plus" compromise with expungement and SBA provisions attached.

2023 (September) — Reverses course; co-sponsors the SAFER Banking Act after Schumer commits to incorporating the HOPE Act for record expungement.

2024 (April) — Welcomes DOJ reclassification of cannabis from Schedule I to Schedule III, but says Congress must go further.

2024 (May) — Reintroduces the CAOA for the third time. Bill again fails to advance.